Adverse events666

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

321 to 340 of 666

Type	Event	Organ system	Group	Affected	At risk	Events
other	Back pain	Musculoskeletal and connective tissue disorders	Stratum 2, Dose Level 1 (16 mg/m^2)	0	3	0
other	Back pain	Musculoskeletal and connective tissue disorders	Stratum 2, Dose Level 2 (22 mg/m^2)	0	11	0
other	Back pain	Musculoskeletal and connective tissue disorders	Stratum 2, Dose Level 3 (28 mg/m^2)	0	12	0
other	Back pain	Musculoskeletal and connective tissue disorders	Stratum 2, Dose Level 4 (36 mg/m^2)	0	6	0
other	Generalized muscle weakness	Musculoskeletal and connective tissue disorders	Stratum 1, Dose Level 1 (10 mg/m^2)	2	13	2
other	Generalized muscle weakness	Musculoskeletal and connective tissue disorders	Stratum 1, Dose Level 2 (16 mg/m^2)	1	6	1
other	Generalized muscle weakness	Musculoskeletal and connective tissue disorders	Stratum 2, Dose Level 1 (16 mg/m^2)	0	3	0
other	Generalized muscle weakness	Musculoskeletal and connective tissue disorders	Stratum 2, Dose Level 2 (22 mg/m^2)	0	11	0
other	Generalized muscle weakness	Musculoskeletal and connective tissue disorders	Stratum 2, Dose Level 3 (28 mg/m^2)	0	12	0
other	Generalized muscle weakness	Musculoskeletal and connective tissue disorders	Stratum 2, Dose Level 4 (36 mg/m^2)	0	6	0
other	Muscle weakness left-sided	Musculoskeletal and connective tissue disorders	Stratum 1, Dose Level 1 (10 mg/m^2)	0	13	0
other	Muscle weakness left-sided	Musculoskeletal and connective tissue disorders	Stratum 1, Dose Level 2 (16 mg/m^2)	0	6	0
other	Muscle weakness left-sided	Musculoskeletal and connective tissue disorders	Stratum 2, Dose Level 1 (16 mg/m^2)	0	3	0
other	Muscle weakness left-sided	Musculoskeletal and connective tissue disorders	Stratum 2, Dose Level 2 (22 mg/m^2)	0	11	0
other	Muscle weakness left-sided	Musculoskeletal and connective tissue disorders	Stratum 2, Dose Level 3 (28 mg/m^2)	1	12	1
other	Muscle weakness left-sided	Musculoskeletal and connective tissue disorders	Stratum 2, Dose Level 4 (36 mg/m^2)	0	6	0
other	Neoplasms benign, malignant and unspecified (incl cysts and polyps) - other, specify	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Stratum 1, Dose Level 1 (10 mg/m^2)	2	13	2
other	Neoplasms benign, malignant and unspecified (incl cysts and polyps) - other, specify	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Stratum 1, Dose Level 2 (16 mg/m^2)	0	6	0
other	Neoplasms benign, malignant and unspecified (incl cysts and polyps) - other, specify	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Stratum 2, Dose Level 1 (16 mg/m^2)	0	3	0
other	Neoplasms benign, malignant and unspecified (incl cysts and polyps) - other, specify	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Stratum 2, Dose Level 2 (22 mg/m^2)	0	11	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Previous page Next page

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02717455/events?page=17

API reference For AI assistants